After Exubera, Uncertainty Reigns
Clinical trials for competing products haven't gone on long enough to assure that these drugs won't affect the lungs. Analysts say the Exubera experience has sensitized the FDA to lung safety.
Among competitors, analysts appear to be the most impressed with the scientific progress of MannKind's Technosphere insulin. But MannKind hasn't found a partner to help absorb the research and development costs.
Back in August, MannKind executives told analysts that collaboration discussions were going slower than expected partly because potential partners were worried that Technosphere might get the same insurer rebuff as Exubera. Late-stage clinical trial results are expected in mid-2008, and MannKind might file an application with the FDA late next year.
The Exubera decision "is very bad" for MannKind because Technosphere represents almost all of its market valuation, says LeCroy. He has a sell rating on MannKind, a buy rating on Nektar and a hold rating on Pfizer."We do not think MannKind will be able to partner [Technosphere] and that the Exubera withdrawal was the final straw," he says. The Exubera fiasco will have a "very limited impact" on Alkermes, which is developing AIR insulin with Lilly, says LeCroy, who has hold ratings on both companies. He says inhaled insulin only accounts for 5% to 10% of Alkermes' market capitalization, adding that the Lilly deal limits Alkermes' risk until the product reaches the market. He forecasts a 2010 launch. Like Exubera, the AIR and Technosphere products use a powdered form of insulin. Denmark's Novo Nordisk is developing a liquid form of inhaled insulin called AERx. The company may issue results of a crucial test in late 2008, says the Danish investment banking firm SEB Enskilda. The firm says the Lilly-Alkermes team should issue late-stage clinical trial results next year. Meanwhile, Nektar hasn't decided on its next move. It can't afford to act on its own, but how many other companies will step in where Pfizer failed? At one point, there was another Exubera partner, but Pfizer paid $1.3 billion in January 2006 to buy out Sanofi-Aventis' (SNY) interest, making the French drugmaker the only winner thus far in the inhaled insulin sweepstakes.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV